A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

BACKGROUND: The efficacy of first-generation protease inhibitor based triple-therapy against hepatitis C virus (HCV) infection is limited in HIV/HCV-coinfected patients with advanced liver fibrosis and non-response to previous peginterferon-ribavirin. These patients have a low chance of achieving a...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Dominique L., Rauch, Andri, Aouri, Manel, Durisch, Nina, Eberhard, Nadia, Anagnostopoulos, Alexia, Ledergerber, Bruno, Müllhaupt, Beat, Metzner, Karin J., Decosterd, Laurent, Böni, Jürg, Weber, Rainer, Fehr, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503454/
https://www.ncbi.nlm.nih.gov/pubmed/26176696
http://dx.doi.org/10.1371/journal.pone.0133028

Ejemplares similares

Ejemplares similares